Roivant Sciences Ltd Market Cap ($20.44 Billion)
Market Cap & Net Worth: Roivant Sciences Ltd (ROIV)
Roivant Sciences Ltd market cap. Roivant Sciences Ltd (NASDAQ:ROIV) has a market capitalization of $20.44 Billion ($20.44 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1229 globally and #518 in its home market, demonstrating a -1.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Roivant Sciences Ltd's stock price $36.91 by its total outstanding shares 715701137 (715.70 Million).
Roivant Sciences Ltd Market Cap History (2020–2026)
Roivant Sciences Ltd market cap history from 2020 to 2026. Data shows growth from $7.28 Billion to $26.42 Billion (23.97% CAGR). Check Roivant Sciences Ltd stock price for real-time trading data and today's change.
Index Memberships
Roivant Sciences Ltd is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.78% | #21 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.05% | #153 of 3165 |
|
S&P Midcap 400
MID
|
$3.34 Trillion | 0.16% | #16 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 1.11% | #15 of 263 |
Weight: Roivant Sciences Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Roivant Sciences Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Roivant Sciences Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash efficiency ratio of Roivant Sciences Ltd for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
534.56x
Roivant Sciences Ltd's market cap is 534.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $7.28 Billion | $67.69 Million | $1.20 Billion | 107.53x | 6.06x |
| 2021 | $7.21 Billion | $23.80 Million | -$809.23 Million | 303.18x | N/A |
| 2022 | $5.72 Billion | $55.29 Million | -$845.26 Million | 103.43x | N/A |
| 2023 | $8.04 Billion | $61.28 Million | -$1.01 Billion | 131.16x | N/A |
| 2024 | $8.47 Billion | $32.71 Million | $4.35 Billion | 258.82x | 1.95x |
| 2025 | $15.53 Billion | $29.05 Million | -$171.98 Million | 534.56x | N/A |
Competitor Companies of ROIV by Market Capitalization
Companies near Roivant Sciences Ltd in the global market cap rankings as of October 31, 2026. See net asset quality index of Roivant Sciences Ltd to understand what proportion of total assets are financed by equity.
Key companies related to Roivant Sciences Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Roivant Sciences Ltd (2020–2026)
Market capitalization of Roivant Sciences Ltd from 2020 to today. Between 2020 and today, Roivant Sciences Ltd's market cap moved from $7.28 Billion to $ 26.42 Billion, with a yearly change of 23.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $26.42 Billion | +70.09% |
| 2025 | $15.53 Billion | +83.43% |
| 2024 | $8.47 Billion | +5.34% |
| 2023 | $8.04 Billion | +40.55% |
| 2022 | $5.72 Billion | -20.73% |
| 2021 | $7.21 Billion | -0.88% |
| 2020 | $7.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Roivant Sciences Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.44 Billion USD |
| MoneyControl | $20.44 Billion USD |
| MarketWatch | $20.44 Billion USD |
| marketcap.company | $20.44 Billion USD |
| Reuters | $20.44 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease… Read more